Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data

Executive Summary

With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.


Related Content

Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
Where Cholesterol Surrogates Stand After ACC '16
PCSK9 Sponsors, Payers In The Ring At ACC
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Outcomes Data For Sanofi/Regeneron’s Praluent May Land In 2016
CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy
IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
Bad News/Good News For Cholesterol: Another Strike Against HDL, But Support For Stricter LDL Targets
Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts